Abstract B18: CXCL10 suppresses tumor angiogenesis and impedes expression of critical angiogenic factors in renal cell carcinoma

2016 ◽  
Author(s):  
Hyun A Jin ◽  
Jun Hyeok Heo ◽  
You Hyun Kang ◽  
Ki Hong Kim ◽  
Kyung Suk Han ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Angiogenesis ◽  
Renal Cell ◽  
Angiogenic Factors

scholarly journals YAP Promotes VEGFA Expression and Tumor Angiogenesis Though Gli2 in Human Renal Cell Carcinoma

2019 ◽  
Vol 50 (4) ◽  
pp. 225-233 ◽  
Author(s):  
Shan Xu ◽  
Haibao Zhang ◽  
Yue Chong ◽  
Bing Guan ◽  
Peng Guo
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Angiogenesis ◽  
Renal Cell ◽  
Human Renal Cell Carcinoma

scholarly journals Regulation of Angiogenic Factors by HDM2 in Renal Cell Carcinoma

2008 ◽  
Vol 68 (2) ◽  
pp. 545-552 ◽  
Author(s):  
Veronica A. Carroll ◽  
Margaret Ashcroft
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Angiogenic Factors

Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma

2007 ◽  
Vol 100 (1) ◽  
pp. 209-214 ◽  
Author(s):  
Tobias Klatte ◽  
Malte Böhm ◽  
Thomas Nelius ◽  
Stephanie Filleur ◽  
Frank Reiher ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Angiogenic Factors

scholarly journals Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma

2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
Alessandro Conti ◽  
Matteo Santoni ◽  
Consuelo Amantini ◽  
Luciano Burattini ◽  
Rossana Berardi ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Angiogenesis ◽  
Targeted Therapies ◽  
Renal Cell ◽  
Mammalian Target Of Rapamycin ◽  
Phosphatidylinositol 3 Kinase ◽  
Von Hippel Lindau ◽  
Angiogenesis Process ◽  
Endothelial Growth Factor

Vascular endothelial growth factor (VEGF) plays a crucial role in tumor angiogenesis. VEGF expression in metastatic renal cell carcinoma (mRCC) is mostly regulated by hypoxia, predominantly via the hypoxia-induced factor (HIF)/Von Hippel-Lindau (VHL) pathway. Advances in our knowledge of VEGF role in tumor angiogenesis, growth, and progression have permitted development of new approaches for the treatment of mRCC, including several agents targeting VEGF and VEGF receptors: tyrosine kinase pathway, serine/threonine kinases,α5β1-integrin, deacetylase, CD70, mammalian target of rapamycin (mTOR), AKT, and phosphatidylinositol 3′-kinase (PI3K). Starting from sorafenib and sunitinib, several targeted therapies have been approved for mRCC treatment, with a long list of agents in course of evaluation, such as tivozanib, cediranib, and VEGF-Trap. Here we illustrate the main steps of tumor angiogenesis process, defining the pertinent therapeutic targets and the efficacy and toxicity profiles of these new promising agents.

229 INHIBITION OF THE GROWTH AND TUMOR ANGIOGENESIS OF RENAL CELL CARCINOMA BY THE STAT3 INHIBITOR WP1066

2011 ◽  
Vol 185 (4S) ◽  
Author(s):  
Akio Horiguchi ◽  
Takako Asano ◽  
Kenji Kuroda ◽  
Akinori Sato ◽  
Junichi Asakuma ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Angiogenesis ◽  
Renal Cell
Sign in / Sign up

Export Citation Format

Share Document